Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Brown Advisory Inc.

Brown Advisory Inc. grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,438 shares of the medical equipment provider’s stock after acquiring an additional 192 shares during the period. Brown Advisory Inc.’s holdings in Hologic were worth $5,319,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Independent Advisor Alliance increased its position in shares of Hologic by 28.6% in the 4th quarter. Independent Advisor Alliance now owns 4,828 shares of the medical equipment provider’s stock worth $345,000 after purchasing an additional 1,073 shares during the last quarter. Panagora Asset Management Inc. boosted its holdings in Hologic by 2.4% in the fourth quarter. Panagora Asset Management Inc. now owns 1,106,644 shares of the medical equipment provider’s stock worth $79,070,000 after purchasing an additional 26,349 shares during the period. Triodos Investment Management BV increased its stake in Hologic by 4.5% during the fourth quarter. Triodos Investment Management BV now owns 23,000 shares of the medical equipment provider’s stock valued at $1,643,000 after purchasing an additional 1,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Hologic by 33.2% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,436 shares of the medical equipment provider’s stock worth $1,317,000 after purchasing an additional 4,596 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Hologic by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 241,283 shares of the medical equipment provider’s stock worth $17,462,000 after buying an additional 10,264 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on HOLX. Raymond James lifted their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Argus upped their target price on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. lifted their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Finally, UBS Group raised their target price on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $74.55 on Wednesday. The firm has a market cap of $17.40 billion, a price-to-earnings ratio of 38.04, a P/E/G ratio of 2.49 and a beta of 1.01. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $76.20 and a 200 day simple moving average of $73.81. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the prior year, the business earned $1.06 earnings per share. Hologic’s revenue for the quarter was down .8% compared to the same quarter last year. As a group, sell-side analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.